AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02896907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Given IV
Study NCT02867345 — intervention group
Intervention type: BIOLOGICAL
Intervention: PD-1 Knockout T Cells
Description: PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
Study NCT02867345 — intervention group
Intervention type: DRUG
Intervention: Cyclophosphamide
Description: Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).
Study NCT02867345 — intervention group
Intervention type: DRUG
Intervention: IL-2
Description: Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
Study NCT00518219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TW
Description: TW,120mg/d
Study NCT05909605 — intervention group
Intervention type: DEVICE
Intervention: sphygmomanometer
Description: Comparison to the ultrasound sensor
Study NCT05909605 — intervention group
Intervention type: DEVICE
Intervention: Arterial Line
Description: Comparison to the ultrasound sensor
Study NCT04359082 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CocoaVia supplement
Description: CocoaVia is a dietary supplement that has concentrated bioflavanols of 225 mg flavanols per pill along with 30 mg theobromine and 10 mg caffeine
Study NCT04359082 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pill
Description: Placebo pill has no bioflavanols with 30 mg theobromine and 10 mg caffeine
Study NCT05286073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic Root Canal Treatment
Description: Root canal shaping procedures were performed. Irrigation was done after each three pecks of endodontic file. After instrumentation (Groups 1-3), the canals were dried with sterile paper points. The dentinal walls were then coated with Sealapex. For vertical root fracture resistance testing, sample preparation was done in acrylic blocks. Then roots were coated with polyvinylsiloxane impression material. After that roots were inserted again into acrylic resin blocks. The acrylic blocks with the vertically aligned roots were mounted in the Instron testing machine. 0.5 mm diameter round tip stainless-steel rod was fixed to the universal testing machine. The universal testing machine was adjusted and vertical compressive force was applied at a crosshead speed of 1mm/min. The Instron tester applied a slowly increasing force, until the root fractured. The maximum amount of force necessary to fracture every sample was recorded in Newton (N).
Study NCT02922634 — intervention group
Intervention type: OTHER
Intervention: Mini Cog
Description: short cognitive screen, short Frailty screen
Study NCT03824925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral Zinc capsule
Description: Look alike cap of corn starch as a placebo of Zinc to be given on day 1 of chemo-radiotherapy
Study NCT03824925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral Zinc capsule
Description: Look alike cap of corn starch as a placebo of Zinc to be given on day 1 of chemo-radiotherapy
Study NCT03824925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zinc Sulfate 220 MG
Description: Zinc sulfate in test group dose was 220 mg which is equivalent to 50 mg of elemental zinc
Study NCT03824925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate 220 MG
Description: Zinc sulfate in test group dose was 220 mg which is equivalent to 50 mg of elemental zinc
Study NCT00418834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe and atorvastatin
Description: ezetimibe 10 mg and atorvastatin 10 mg daily for 12 weeks
Study NCT00418834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: Atorvastatin 20 mg daily for 6 weeks, and up-titrated to atorvastatin 40 mg daily for an additional 6 weeks
Study NCT00418834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (unspecified)
Description: Placebo (unspecified) daily for 12 weeks
Study NCT01996306 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.
Study NCT01996306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPT-11 (Irinotecan)
Description: 150-180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle.
Study NCT01584531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rigosertib
Description: Rigosertib sodium will be available as soft gel capsules in strengths of 280 mg and 70 mg. Rigosertib will be administered on an outpatient basis.~Patients will take a 560 mg dose (e.g., 2 x 280 mg capsules) of oral rigosertib in the morning and 280 mg dose (e.g., 1 x 280 mg capsules) of oral rigosertib every day of 21-day cycles. Rigosertib should be taken in a fasting state (defined by at least 30 minutes before next meal) BID at 12 hr intervals (with a window of 2 hr). Any vomited dose will be reported as a missed dose.~The patient will fill a diary indicating the day and time of drug intake.
Study NCT02237742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06427878
Description: Intravenous, 100 micrograms, single dose, 30 minute infusion
Study NCT02842463 — intervention group
Intervention type: OTHER
Intervention: 2 times : 6-minute stepper test with a rest of 20min between each test.
Study NCT03740620 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bevel facing the cephalad direction of the patient
Description: The bevel of the nasotracheal tube facing cephalad direction of the patient
Study NCT03740620 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bevel facing leftward of the patient
Description: The bevel of the nasotracheal tube facing the left side of the patient
Study NCT01878721 — intervention group
Intervention type: RADIATION
Intervention: PET/CT
Description: positron emission tomography/computed tomography
Study NCT05039437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MGF-4
Description: Participants were instructed to take 2 capsules of MGF-4 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.
Study NCT05039437 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MGF-7
Description: Participants were instructed to take 2 capsules of MGF-7 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.
Study NCT03680079 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group education sessions
Description: Peer support and interaction both in-person during group education sessions and online via social media platforms
Study NCT03971578 — intervention group
Intervention type: OTHER
Intervention: No Intervention Provided
Description: No Intervention Provided
Study NCT03275584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-13 ammonia intravenous injection
Description: Participants will receive two injections of N-13 ammonia, once at rest and once at stress before undergoing positron emission tomography myocardial perfusion imaging
Study NCT00149149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zinc Carnosine coadministered with Indomethacin
Study NCT01996306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU Bolus
Description: 400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
Study NCT00149149 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo coadministered with Indomethacin
Study NCT00743470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Description: lopinavir/ritonavir tablet; see arm for intervention description
Study NCT02798835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Local anesthetic to be used by surgeon as local infiltration and by anesthesiologist in adductor canal block.
Study NCT02798835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: To be given intravenously at time of nerve block to one of the study arms.
Study NCT01081145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release Guanfacine Hydrochloride
Description: The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on age and weight.
Study NCT01081145 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on age and weight.
Study NCT01315314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Balance, Fresenius Medical Care, Germany
Description: low glucose degradation product (GDP)-containing peritoneal dialysis fluid (PDF)
Study NCT02542852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir 300 mg + ritonavir 100 mg + dolutegravir 50 mg
Description: Switch to single arm treatment atazanavir-ritonavir 300-100 mg + dolutegravir 50 mg therapy for 24 weeks
Study NCT04609618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Appscent Device
Description: computer-controlled, low pressure compressed air based, with disposable odorant capsules solution provided an odor environment at the nose,
Study NCT01839578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation)
Description: Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~Ci-Ca protocole for MultiFiltrate® CRRT machine :~* 4% trisodium citrate solution~* Calcium chloride solution (100 mmol/L)~* Dialysate flow rate: 35 ml/kg/h~* Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of 3~* Citrate infusion titrated to maintain postfilter ionized calcium between 0.25 and 0.35 mmol/L.~* Calcium chloride infusion titrated to maintain systemic ionized calcium between 1.12 and 1.2 mmol/L.~* Blood flow adapted to the acid-base status
Study NCT01839578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin)
Description: Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~* Continuous infusion of unfractionated heparin: starting infusion rate at 600 IU/h then adjusted to maintain partial thromboplastin time at 1-1.4 times the normal value.~* Standard dialysate for CRRT : Prismasol® K2 solution~* Dialysate flow rate: 35 ml/kg/h~* Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of
Study NCT02929485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: Tolcapone 200mg (single dose) administered at study visit
Study NCT02929485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (200mg) administered at study visit
Study NCT02929485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Description: Drug: Bromocriptine 1.25 mg (single dose) administered at study visit
Study NCT03161990 — intervention group
Intervention type: PROCEDURE
Intervention: Transgluteal approach to the hip joint
Description: Operative approach to the hip joint where the abductors are partly detached from the greater trochanter and the hip joint is approached through the anterior part of the capsule.
Study NCT03161990 — intervention group
Intervention type: PROCEDURE
Intervention: Posterior approach to the hip joint
Description: Operative approach to the hip joint where the short external rotators are detached from the greater trochanter and the hip joint is approached through the posterior part of the capsule.
Study NCT01059877 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1072nm infrared Photobiomodulation
Description: 1072nm infrared light delivering 2.6 Joules (2.6J)/sq cm over a 6 minute treatment period.
Study NCT01059877 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Photobiomodulation SIMULATED
Description: Device mounted and procedure followed but with no stimulation.
Study NCT01576523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor - single intravenous dose
Description: A single intravenous dose of C1-esterase inhibitor (Berinert) at 20 units per kg body weight will be administered to all subjects prior to receiving the first dose of subcutaneous C1-esterase inhibitor.
Study NCT01576523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor - subcutaneous low dose
Description: A low dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
Study NCT01576523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor - subcutaneous medium dose
Description: A medium dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
Study NCT01576523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor - subcutaneous high dose
Description: A high dose of C1-esterase inhibitor will administered subcutaneously twice a week for four weeks.
Study NCT00639002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 25 mg
Description: Ruxolitinib was supplied as 5 and 25 mg tablets.
Study NCT00639002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 40 mg
Description: Dexamethasone was obtained commercially by Investigators in tablet strengths of 20 or 40 mg.
Study NCT05153135 — intervention group
Intervention type: DRUG
Intervention: Ribociclib
Description: Participants who initiated CDK4/6i therapy
Study NCT05153135 — intervention group
Intervention type: DRUG
Intervention: Palbociclib
Description: Participants who initiated CDK4/6i therapy
Study NCT05153135 — intervention group
Intervention type: DRUG
Intervention: Abemaciclib
Description: Participants who initiated CDK4/6i therapy
Study NCT03950869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Expectation Manipulation
Description: Participants are watching a video tape of a trauma expert who provides selective information on the development of intrusive memories. This video tape aims to increase positive expectations.
Study NCT03950869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative Expectation Manipulation
Description: Participants are watching a video tape of a trauma expert who provides selective information on the development of intrusive memories. This video tape aims to increase negative expectations.
Study NCT00745446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm Venous Occlusion Plethysmography
Description: Forearm venous occlusion plethysmography with intra-arterial infusion of Acetylcholine (5-20mcg/min), bradykinin (30-300mcg/min), sodium nitroprusside (2-8mcg/min) and Verapamil (2-10 mcg/min) into non-dominant brachial artery
Study NCT04191486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-817MA
Description: 224mg T-817MA orally once daily for first 4 weeks, and then 448mg T-817MA orally once daily for the following weeks.
Study NCT04191486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study NCT01430611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A and C) Polysaccharide Vaccine
Description: 0.5 mL, Subcutaneous
Study NCT01430611 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (Groups A and C) Polysaccharide Vaccine
Description: 0.5 mL, Subcutaneous
Study NCT01245452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab (8 mg/kg monthly from week 0 to 20)
Study NCT01245452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
Study NCT06175572 — intervention group
Intervention type: DEVICE
Intervention: coronary physiological indices
Description: coronary physiological indices
Study NCT00886145 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vibration: Right Leg and No Vibration: Left Leg.
Description: Vibration- right leg: The subjects will undergo a mechanical vibration intervention (Juvent Vibrating plate) in the seated position, with a load of 50lbs will be added to the right leg by using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month.~No Vibration-left leg: At each vibration training session, the left leg will serve as a control with a load of 50lbs added to the left leg using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month.
Study NCT04674449 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Disclosure of IDP results
Description: The results of the adjunctive IDP performed at time of invasive coronary angiography are made available to the catheter laboratory clinician, to aid in the diagnostic process.
Study NCT04674449 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: IDP performed but results not disclosed
Description: The results of the IDP performed at the time of invasive coronary angiography are concealed from the catheter laboratory clinician who will be blinded. The patient is managed according to standard of care.
Study NCT00743470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifabutin
Description: rifabutin capsule; see arms for intervention description
Study NCT00841633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induced hypertension with norepinephrine
Description: Hypertension will be induced with norepinephrine. Administration of norepinephrine results in vasoconstriction, leading to an increase in blood pressure. The normal blood pressure of the patient will be calculated as the average MAP of the day before the start of the study. To achieve the intended hypertension (30 mmHg above the normal MAP for patients allocated to index group 2) in most cases a dose of 100-300 ng/kg/minute must be administered. Norepinephrine will be started on a dose of 100 ng/kg/minute, after which the dosing will be adjusted to achieve the desired blood pressure level. The maximum dose to be used in the study is 1000 ng/kg/minute. Norepinephrine is administered through the central venous catheter.
Study NCT00765973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Liposomes Injection (TLI)
Description: TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2)
Study NCT00765973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Liposomes Injection (TLI)
Description: TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2)
Study NCT01996306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU Infusion
Description: 2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
Study NCT01996306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: l-LV (dl-LV)
Description: 200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
Study NCT01996306 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 7.5mg/kg IV intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on Day 1 of a 3-week cycle.
Study NCT01996306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT-11 (Irinotecan)
Description: 150-200 mg/m2 intravenously administered over 90 minutes on day 1 of a 3-week cycle.
Study NCT01996306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1600mg/m2/day oral on day 1 (evening) to day 15 (morning)of a 3-week cycle.
Study NCT01441921 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pistachios
Description: Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.~Total duration of intervention and follow-up is nine months.
Study NCT01441921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control diet
Description: Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.~Total duration of intervention and follow-up is nine months.
Study NCT03806179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 MBq/kg Betalutin
Description: 10 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
Study NCT03806179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 MBq/kg Betalutin
Description: 15 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
Study NCT02307669 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: INCA feedback
Description: The study team have developed a device which is attached to inhalers that makes an audio recording of the inhaler being used. Analysis of this audio data provides objective evidence of the time of inhaler use, technique of use and the peak inspiratory flow the patient makes each time they use their inhaler. Our preliminary experiences with the information obtained from this device indicate that adherence is poor in patients with severe asthma due to any one the following issues poor time of use, errors in handling and low peak inspiratory flow rates.